Valuation: Valneva SE

Market Cap 485M 541M 449M 407M 759M 51.54B 769M 5.37B 2.14B 26.97B 2.03B 1.99B 85.61B P/E 2026 *
-5.88x
P/E 2027 * 9.27x
Enterprise Value 620M 691M 573M 519M 969M 65.78B 981M 6.85B 2.73B 34.42B 2.59B 2.54B 109B EV / Sales 2026 *
4.11x
EV / Sales 2027 * 1.94x
Free-Float
89.58%
Yield 2026 *
-
Yield 2027 * -
1 day-0.43%
1 week+6.25%
Current month-5.94%
1 month-5.14%
3 months+15.60%
6 months+9.49%
Current year-31.44%
1 week 2.33
Extreme 2.326
2.58
1 month 2.33
Extreme 2.326
2.77
Current year 2.03
Extreme 2.033
5.15
1 year 2.03
Extreme 2.033
5.15
3 years 1.73
Extreme 1.726
7.17
5 years 1.73
Extreme 1.726
29.7
10 years 1.73
Extreme 1.726
29.7
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 28/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 19/12/2023
Director/Board Member 75 06/03/2013
Chairman 65 19/12/2023
Date Insider Type Main position Quantity % Market Cap. Importance
27/01/26 Sell

Chief Technology Officer

11,800 0.0069%
26/01/26 Sell

Chief Financial Officer

11,800 0.0069%
19/01/26 Exercice

Chief Technology Officer

82,899 0.0482%
Change 5-day change 1-year change 3-year change Capi.($)
-0.43%+6.25%-35.60%-51.11% 541M
+0.34%-3.03%+37.45%+61.06% 64.14B
+1.28%+2.91%+12.50%+84.32% 55.53B
+1.30%+1.72%+12.98%+105.14% 53.03B
-0.53%-0.28%+27.41%+56.66% 45.99B
-0.13%-2.07%+18.90%+100.61% 42.45B
+1.22%+1.73%+229.08%+940.52% 40.45B
-0.26%-4.20%+10.86%+45.18% 32.25B
-1.89%+44.57%+106.40%+92.72% 34.47B
-2.72%-8.79%+22.58%-5.63% 24.23B
Average -0.14%+3.80%+44.26%+142.95% 39.31B
Weighted average by Cap. +0.14%+3.13%+50.01%+161.75%

Financials

2026 *2027 *
Net sales 151M 168M 139M 126M 236M 16.01B 239M 1.67B 664M 8.38B 631M 617M 26.6B 283M 316M 262M 237M 443M 30.07B 449M 3.13B 1.25B 15.74B 1.18B 1.16B 49.96B
Net income -81.35M -90.67M -75.21M -68.12M -127M -8.64B -129M -899M -358M -4.52B -340M -333M -14.35B 53.02M 59.1M 49.02M 44.4M 82.95M 5.63B 83.95M 586M 233M 2.95B 222M 217M 9.35B
Net Debt 134M 150M 124M 112M 210M 14.24B 212M 1.48B 591M 7.45B 561M 549M 23.66B 62.86M 70.06M 58.11M 52.63M 98.33M 6.67B 99.52M 695M 277M 3.49B 263M 257M 11.08B
Projected Income Statement - Annual - Valneva SE
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
620
Date Price Change Volume
29/10/26 €2.546 -0.55% 167,419
28/10/26 €2.560 +3.35% 401,463
27/10/26 €2.477 +2.40% 308,611
26/10/26 €2.419 +4.00% 497,506
23/10/26 €2.326 -3.04% 355,632
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Valneva SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.560EUR
Average target price
6.200EUR
Spread / Average Target
+142.19%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Valneva SE